文献速递白血病

高三尖杉酯碱联合伊达比星巩固治疗首次完全缓解的急性髓系白血病:一项随机对照试验

High-dose cytarabine with idarubicin consolidation for acute myeloid leukemia in first complete remission: a randomized controlled trial.
PubMed 文献 · Leukemia · 2025-05-28

该随机对照试验将407例首次完全缓解的AML患者1:1分配至高剂量阿糖胞苷联合伊达比星(IA3+3)组或高剂量阿糖胞苷(HDAC)组作为首次巩固治疗。IA3+3组首次巩固后MRD阴性率65.2% vs HDAC组53.2%(P=0.009),3年累积复发率22.6% vs 34.0%(P=0.014),DFS 68.4% vs 52.9%(P=0.003),OS 75.5% vs 69.6%(P=0.18)。IA3+3方案较HDAC获得更深缓解并减少复发。

要点

  • IA3+3组首次巩固后MRD阴性率65.2%,高于HDAC组的53.2%(P=0.009)。
  • IA3+3组3年累积复发率22.6%,低于HDAC组的34.0%(P=0.014)。
  • IA3+3组3年DFS为68.4%,优于HDAC组的52.9%(P=0.003);两组OS无显著差异(P=0.18)。

核心结论

  • IA3+3方案较HDAC方案获得更深缓解并减少复发,更深缓解改善DFS并转化为治疗优势,且接受allo-HSCT的患者更少。

研究设计与样本

  • 随机对照试验,2018年11月至2021年12月共纳入407例首次完全缓解的AML患者,1:1随机分配至IA3+3组(n=204)或HDAC组(n=203)。
  • IA3+3方案为伊达比星10 mg/m2 d1-3联合阿糖胞苷2 g/m2每12小时 d1-3;HDAC方案为阿糖胞苷3 g/m2每12小时 d1-3;主要终点为首次巩固后MRD阴性率。

主要发现

  • 首次巩固后MRD阴性率IA3+3组65.2%(95%CI 58.6-71.8%)vs HDAC组53.2%(95%CI 46.3-60.1%)(P=0.009)。
  • 3年累积复发率IA3+3组22.6%(95%CI 16.8-29.0%)vs HDAC组34.0%(95%CI 27.1-41.1%)(P=0.014)。
  • 3年DFS IA3+3组68.4%(95%CI 61.5-75.3%)vs HDAC组52.9%(95%CI 45.4-60.5%)(P=0.003)。
  • 3年OS IA3+3组75.5%(95%CI 69.0-82.1%)vs HDAC组69.6%(95%CI 62.4-76.7%)(P=0.18)。
  • 治疗相关死亡率IA3+3组8.8%(95%CI 5.2-13.6%)vs HDAC组13.0%(95%CI 8.5-18.5%)(P=0.23);接受allo-HSCT者IA3+3组87例(43%)vs HDAC组114例(56%)(P=0.006)。

关键数值与推荐

  • 首次巩固后MRD阴性率IA3+3组65.2% vs HDAC组53.2%(P=0.009)。
  • 3年累积复发率IA3+3组22.6% vs HDAC组34.0%(P=0.014)。
  • 3年DFS IA3+3组68.4% vs HDAC组52.9%(P=0.003)。
  • 3年OS IA3+3组75.5% vs HDAC组69.6%(P=0.18)。
  • 治疗相关死亡率IA3+3组8.8% vs HDAC组13.0%(P=0.23)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Whether adding anthracycline to intermediate- or high-dose cytarabine as consolidation is beneficial remains unclear in acute myeloid leukemia (AML). Eligible AML patients in first complete remission were randomly assigned (1:1) to receive either high-dose cytarabine with idarubicin (IA3 + 3) (idarubicin 10 mg/m2, d1-3 and cytarabine 2 g/m2, every 12 h, d1-3) or high-dose cytarabine (HDAC) (cytarabine 3 g/m2, every 12 h, d1-3) regimens as first consolidation. The primary endpoint was the rate of negative measurable residual disease (MRD-) after first consolidation. Between November 2018 and December 2021, 407 patients were assigned to IA3 + 3 (n = 204) or HDAC (n = 203) groups. MRD- after first consolidation for IA3 + 3 and HDAC groups was 65.2% (95%CI: 58.6-71.8%) and 53.2% (46.3-60.1%) (P = 0.009). The 3-year cumulative incidence of relapse was 22.6% (95%CI :16.8-29.0%) and 34.0% (27.1-41.1%) (P = 0.014), DFS was 68.4% (61.5-75.3%) and 52.9% (45.4-60.5%) (P = 0.003), OS was 75.5% (69.0-82.1%) and 69.6% (62.4-76.7%) (P = 0.18) and treatment-related mortality was 8.8% (5.2-13.6%) and 13.0% (8.5-18.5%) (P = 0.23) in two groups, respectively. Eighty-seven (43%) and 114 (56%) patients underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT), respectively (P = 0.006). IA3 + 3 regimen results in deeper remissions and reduces relapse compared to HDAC. This deeper remission improves DFS and translates into treatment advantage, with fewer patients undergoing allo-HSCT. (ClinicalTrials.gov, NCT03620955).

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Feng Z, Du J, et al. High-dose cytarabine with idarubicin consolidation for acute myeloid leukemia in first complete remission: a randomized controlled trial. Leukemia. 2025. PMID: 40437173. doi:10.1038/s41375-025-02655-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。